Optimizing Bispecific Antibody Therapy for Acute Leukemias |
Fred Hutchinson Cancer Research Center / Roland Walter, MD, PhD & James Olson, MD, PhD |
Innovation Grants |
2015 |
Washington |
Functional Analysis and Therapeutic Targeting of STAG2 Mutations in Ewing sarcoma |
Georgetown University / Todd Waldman, MD, PhD |
Innovation Grants |
2015 |
District of Columbia |
Identifying how Pre-existing Anti-Therapeutic Antibodies (PATA) are Associated with Better Outcome in a Clinical Trial of ADCC-inducing Anti-GD2 mAb |
University of Wisconsin - Madison / Paul Sondel, MD, PhD |
Innovation Grants |
2015 |
Wisconsin |
Antibody Targeted Natural Killer Cell-Derived Extracellular Vesicles for the Treatment of Childhood Acute Lymphoblastic Leukemia and Neuroblastoma |
Children’s Hospital Los Angeles / Robert Seeger, MD & Alan Wayne, MD |
Innovation Grants |
2015 |
California |
Preclinical Development of Atr Inhibitor VE-822, Delivered Systemically in Nanoparticles, for Medulloblastoma Therapy |
University of North Carolina / Timothy Gershon, MD, PhD |
Innovation Grants |
2015 |
North Carolina |
Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma |
Virginia Commonwealth University / Anthony Faber, MD & Yael Mosse, MD (CHOP) |
Innovation Grants |
2015 |
Virginia |
Single Cell Analysis of Leukemia Initiation |
Stanford University / Michael Cleary, MD |
Innovation Grants |
2015 |
California |
Transcriptional Effectors of Activated RAS Signaling in Juvenile Myelomonocytic Leukemia |
Boston Children’s Hospital / Alan Cantor, MD, PhD |
Innovation Grants |
2015 |
Massachusetts |
Synergistic Differentiation Therapy in Neuroblastoma |
Duke University / Gerard Blobe, M.D./Ph.D |
Innovation Grants |
2015 |
North Carolina |
Enhancing Effectiveness of Immune Checkpoint Therapy in Neuroblastoma |
Children’s Hospital Los Angeles / Shahab Asgharzadeh, MD |
Innovation Grants |
2015 |
California |